KPV — α-MSH(11-13) C-Terminal Anti-Inflammatory Tripeptide

Discovery and Background

KPV — the tripeptide Lysine-Proline-Valine — is the carboxy-terminal fragment spanning positions eleven through thirteen of alpha-melanocyte-stimulating hormone (α-MSH). The parent molecule, a tridecapeptide derived from pro-opiomelanocortin (POMC), has long been recognised as one of the body's endogenous anti-inflammatory signals. Work during the 1980s and early 1990s, associated in part with Mac Hadley's laboratory and subsequently expanded by Böhm and Brzoska at Charité Berlin, established that the biological potency of α-MSH could be localised to its C-terminal tripeptide [PMID:8090706].

This finding was counterintuitive at the time. The central tripeptide His-Phe-Arg-Trp (positions six to nine) is the canonical melanocortin receptor-binding motif responsible for pigmentation and pituitary signalling. The discovery that Lys-Pro-Val at the opposite terminus independently reproduced anti-inflammatory activity — without significant melanocortin receptor binding — opened the possibility of a receptor-independent or indirect anti-inflammatory pathway. Subsequent decades of cell-culture and rodent work have substantiated that view, positioning KPV as a structurally minimal, mechanistically distinct fragment with therapeutic potential in inflammatory conditions of the gut, skin, and joints.

Because it is a tripeptide of only three residues with a molecular weight of roughly 342.4 Da, KPV does not encounter the enzymatic barriers that doom most peptides on the oral route. This small size is central to its pharmacokinetic profile and distinguishes it from the vast majority of research peptides.

---

Mechanism of Action

NF-κB Suppression and Cytokine Downregulation

The dominant anti-inflammatory mechanism attributed to KPV is inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signalling cascade. NF-κB is a master transcription factor that, when activated by stimuli such as bacterial lipopolysaccharide (LPS), TNF-α, or IL-1β, drives expression of a wide inflammatory gene network including TNF-α itself, interleukin-6 (IL-6), interleukin-8 (IL-8/CXCL8), and inducible nitric oxide synthase (iNOS).

In monocyte and macrophage cell lines, KPV at nanomolar to low micromolar concentrations blunts nuclear translocation of the p65 NF-κB subunit, reducing transcription of pro-inflammatory cytokines without fully ablating baseline immune surveillance [PMID:8090706]. The peptide also modulates the MAPK pathway — specifically reducing phosphorylation of p38 and ERK — providing a secondary anti-inflammatory brake.

Unlike α-MSH itself, KPV does not appreciably bind MC1R, MC3R, or MC4R in competitive binding assays. This means its anti-inflammatory effect is independent of cAMP/PKA signalling through melanocortin receptors in many cell types, though some studies suggest low-affinity engagement in specific contexts. The weight of evidence points to a direct intracellular or membrane-proximal mechanism that may involve interaction with the NF-κB co-activator IκB kinase (IKK) complex.

Oral Bioavailability via PepT1

Perhaps the most pharmacologically remarkable property of KPV is its verified oral bioavailability mediated by the intestinal oligopeptide transporter PepT1 (SLC15A1). PepT1 is an apical membrane transporter expressed densely in enterocytes of the small intestine and, critically, upregulated in inflamed colonic epithelium. Its physiological role is the absorption of di- and tripeptides from dietary protein digestion using an electrochemical proton gradient. KPV, being a tripeptide of appropriate size and charge, is recognised as a PepT1 substrate and actively transported across the intestinal epithelium into the portal circulation [PMID:18088084].

This is exceptional in the peptide research landscape. Most peptide compounds — BPC-157 being a partial exception through different mechanisms — rely on subcutaneous injection because the gastrointestinal tract degrades them before meaningful absorption can occur. KPV's tripeptide brevity means there is little sequence for luminal peptidases to act upon, and active PepT1 transport rescues what survives. Dalmasso and colleagues demonstrated that KPV encapsulated in nanoparticles and delivered orally reached inflamed colonic tissue and reduced inflammatory markers in murine colitis — establishing proof-of-principle for targeted gut delivery [PMID:18088084].

---

Researched Applications

Inflammatory Bowel Disease and Colitis

The most extensively documented application of KPV in preclinical literature is in models of intestinal inflammation. In the dextran sodium sulfate (DSS)-induced colitis mouse model — a standard surrogate for human ulcerative colitis — oral and intracolonic KPV administration consistently reduced histological damage scores, colon weight ratios, mucosal neutrophil infiltration, and tissue levels of TNF-α and IL-6 [PMID:18088084]. Kannengiesser and colleagues showed that these effects were dose-dependent and reproducible across multiple experimental replicates.

The upregulation of PepT1 in inflamed intestinal tissue is particularly noteworthy: the more severely inflamed the mucosa, the greater the transporter expression and potentially the greater the KPV uptake. This creates a self-targeting pharmacokinetic property that has attracted interest from gastrointestinal researchers. KPV may preferentially accumulate in diseased tissue relative to healthy gut wall.

Atopic Dermatitis and Cutaneous Inflammation

Böhm, Brzoska, and colleagues at Charité demonstrated that topical and systemic KPV application reduced the magnitude of contact hypersensitivity reactions and attenuated inflammatory cytokine production in keratinocyte and melanocyte cultures. This skin-directed research places KPV within the same anti-inflammatory territory as α-MSH itself, which has long been studied for its role in UV-induced and immune-mediated dermatitis.

The small size of KPV also raises the possibility of transdermal penetration — a route not typically accessible to larger peptides — though penetration enhancement remains experimental.

Post-Surgical and Systemic Inflammatory States

Cell-based and rodent studies have examined KPV's capacity to blunt systemic inflammatory responses triggered by LPS challenge and surgical trauma surrogates. Cytokine suppression in macrophage lines is consistent and reproducible. Whether this translates to clinically meaningful systemic effects in humans remains untested in controlled trials.

---

Dosing and Administration

Oral: Anecdotal research-context protocols typically reference 200–500 µg per day in divided doses, taken on an empty stomach to maximise PepT1-mediated absorption. Some protocols use 200 µg twice daily for gut-focused applications. Oral administration capitalises on the PepT1 transporter mechanism and is the route most consistent with the preclinical IBD literature.

Subcutaneous: For systemic or non-gut applications, 200–500 µg once daily via subcutaneous injection is the range appearing in research discussions. Plasma half-life is short — tripeptides are cleared rapidly — making precise timing less consequential than with longer-acting compounds.

Cycle length: Preclinical models typically run two to four weeks. Human research-context reports are insufficient to define optimal cycle length; conservative protocols reference four to eight week periods with reassessment.

No human dose-finding trials exist. All dosing information is extrapolated from animal study effective doses with allometric scaling and must be regarded as entirely speculative at this stage.

---

Safety Profile

KPV has no known intrinsic toxicity signal in cell culture or rodent studies at research doses. Its short sequence and rapid metabolism into constituent amino acids (lysine, proline, valine) — all ordinary dietary amino acids — means downstream metabolites carry no pharmacological concern.

The absence of significant melanocortin receptor binding means the side-effect profile of α-MSH (nausea, sexual arousal, flushing at pharmacological doses) is largely absent for KPV at comparable molar concentrations. No pigmentation effects have been documented.

Theoretical risks include immunomodulatory consequences in individuals with active infection, given that suppression of NF-κB will attenuate some aspects of the innate immune response. Caution is warranted in immunocompromised individuals. As with all research peptides, the absence of long-term human safety data is a fundamental limitation.

---

UK Regulatory Status

KPV is an unapproved research compound in the United Kingdom, United States, and European Union. It is not licensed as a medicinal product by the MHRA, FDA, or EMA. It cannot lawfully be sold or supplied for human use. It is available for laboratory and in vitro research purposes only, under applicable research exemptions.

Individuals in the UK should be aware that the Medicines Act 1968 and Human Medicines Regulations 2012 restrict the supply of unlicensed medicinal products. Possession for personal use is not criminalised under current UK law, but supply channels warrant careful scrutiny. Any product presented as "for human consumption" is in breach of MHRA requirements.

---

Reconstitution and Preparation

Oral Capsule Preparation

For oral research use, KPV lyophilised powder is typically weighed using a high-precision balance (resolution of 0.01 mg or better) and combined with an appropriate carrier. Common practice involves filling size-1 or size-0 gelatin or HPMC capsules with measured KPV powder, optionally blended with microcrystalline cellulose as a bulking agent to aid accurate dosing at sub-milligram quantities.

Taking oral KPV on an empty stomach — at least 30 minutes before food — is theoretically preferable: competing dietary di/tripeptides will occupy PepT1 transporter capacity and may reduce KPV absorption. No controlled human pharmacokinetic data confirm this, but it is consistent with known PepT1 competition dynamics.

Subcutaneous Reconstitution

If using lyophilised KPV for injection, reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a ratio calculated for the target working concentration — typically 0.5–1 mg/mL. Swirl gently; do not vortex. Store reconstituted solution refrigerated at two to eight degrees Celsius; use within fourteen days. Draw through a sterile syringe filter (0.22 µm) if particulates are visible.

---

Frequently Asked Questions

Is KPV truly bioavailable orally? Preclinical evidence strongly supports PepT1-mediated intestinal absorption, particularly in inflamed tissue. Human pharmacokinetic data do not yet exist. The oral route is mechanistically plausible in a way that is rare for peptides, but "plausible" is not "proven in humans."

How does KPV compare to BPC-157 for gut inflammation? The two peptides are mechanistically distinct. BPC-157 acts primarily through nitric oxide pathways, angiogenesis, and growth factor modulation. KPV acts via NF-κB suppression. Their preclinical profiles in colitis models are broadly complementary, which is why they appear together in combination stack discussions.

Can KPV be taken long-term? No long-term human data exist. Its metabolic fate into common dietary amino acids is reassuring, but immunosuppressive effects over extended periods are unstudied. Short research-context cycles with breaks are consistent with a conservative approach.

Does KPV affect skin pigmentation? No. Pigmentation requires MC1R activation by the His-Phe-Arg-Trp motif absent in KPV. Tanning or hyperpigmentation is not an expected effect.

Is refrigeration required for unmixed KPV powder? Lyophilised powder is stable at room temperature for short periods but is best stored at minus twenty degrees Celsius away from light and moisture for long-term stability. Reconstituted solution requires refrigeration.

---

Related Stacks

KPV is most often researched in the context of gut mucosal healing and systemic inflammatory modulation. For curated combination protocols:

• KPV + LL-37 Gut Healing Stack — pairs KPV's NF-κB suppression with LL-37's antimicrobial and epithelial barrier-repair activity for comprehensive mucosal support research.
• BPC-157 + KPV + Thymosin Alpha-1 Immune Stack — a three-compound investigational protocol targeting gut integrity, inflammatory resolution, and innate immune modulation concurrently.

Source research-grade KPV

KPV — α-MSH(11-13) C-Terminal Anti-Inflammatory Tripeptide is sold for laboratory and in vitro research use only. UK regulatory status: Unapproved research compound in UK, US, EU. Laboratory and in vitro research use only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk